Liquid polymer delivery system for extended administration of drugs
Liquid polymer pharmaceutical compositions with a biodegradable liquid polyester that has a carboxylic acid end group, a biocompatible solvent, and an active pharmaceutical agent are useful for administration into the body to provide extended long term release of the drug.
1. An extended release pharmaceutical composition for administration into the body of an animal or human, comprising:
a biodegradable liquid polyester having a carboxylic acid end group;
a biocompatible organic solvent or combination of solvents; and
an active pharmaceutical agent,
wherein:
the extended release pharmaceutical composition is formulated to release the active pharmaceutical agent for a period of one month or greater;
the extended release pharmaceutical composition is free of a polyester without a carboxylic acid end group; and
the biodegradable liquid polyester comprises lactide residues and monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof.
2. The extended release pharmaceutical composition of claim 1 , wherein the carboxylic acid end group is formed from an initiator that is selected from the group consisting of GABA (gamma-amino butyric acid), GHB (gamma-hydroxybutyric acid), lactic acid, glycolic acid, citric acid, and undecylenic acid.
3. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester comprises at least about 50% lactide residues.
4. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester comprises about 75% lactide residues.
5. The extended release pharmaceutical composition of claim 1 , wherein the monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof are in an amount less than about 50%.
6. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester comprises about 25% monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof.
7. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester is selected from the group consisting of 75:25 lactide:caprolactone and 75:25 lactide:trimethylene carbonate.
8. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester has a weight-average molecular weight between about 5 kDa and about 40 kDa.
9. The extended release pharmaceutical composition of claim 1 , wherein the biocompatible organic solvent or combination of solvents is selected from the group consisting of N-methyl-2-pyrrolidone (NMP), 2-pyrrolidone, N-ethyl-2-pyrrolidone, N-cycylohexyl-2-pyrrolidone, N-hydroxyethyl-2-pyrrolidone, dimethyl acetamide, dimethyl formamide, acetic acid, lactic acid, ethanol, propanol, methyl lactate, ethyl lactate, methyl acetate, diethylene glycol monomethyl ether, glycofurol, glycerol formal, isopropylidene glycerol, dimethyl sulfoxide, ε- caprolactone, butyrolactone, propylene glycol, polyethylene glycol, glycerol, 1,3-butyleneglycol, methoxypolyethylene glycol, methoxypropylene glycol, acetone, methyl ethyl ketone, tetrahydrofuran and combinations thereof.
10. The extended release pharmaceutical composition of claim 1 , wherein the composition comprises between about 20 wt % and about 40 wt % of the biodegradable liquid polyester and between about 40 wt % and about 60 wt % of the biocompatible organic solvent or combination of solvents.
11. The extended release pharmaceutical composition of claim 1 , wherein the active pharmaceutical agent is selected from a hydrophobic small molecule drug and a polymeric drug.
12. A method of forming a biodegradable, non-solid implant in situ in a body, comprising injecting the extended release pharmaceutical composition of claim 1 into the body.
13. A method of delivering an active pharmaceutical agent to a body, comprising injecting the extended release pharmaceutical composition of claim 1 into the body.
14. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester has a weight-average molecular weight between about 10 kDa and about 40 kDa.
15. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester has a weight-average molecular weight between about 15 kDa and about 40 kDa.
16. The extended release pharmaceutical composition of claim 1 , wherein the extended release pharmaceutical composition is formulated to release the active pharmaceutical agent for a period of three months or greater.
17. The extended release pharmaceutical composition of claim 1 , wherein a duration of release of the active pharmaceutical agent from the composition is longer than a duration of release obtained from a composition comprising a biodegradable liquid polyester without a carboxylic acid end group.
18. The extended release pharmaceutical composition of claim 1 , wherein the biodegradable liquid polyester comprises at least about 50% lactide residues and monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof.
19. A liquid polymer pharmaceutical composition for administration into the body of an animal or human, comprising:
a biodegradable liquid polyester having a carboxylic acid end group and at least about 50% lactide residues and monomer residues selected from the group consisting of caprolactone, trimethylene carbonate, and combinations thereof;
a biocompatible organic solvent or combination of solvents; and
an active pharmaceutical agent,
wherein:
the liquid polymer pharmaceutical composition is formulated to release the active pharmaceutical agent for a period of one month or greater; and
the biodegradable liquid polyester is the only polyester in the liquid polymer pharmaceutical composition.
20. The liquid polymer pharmaceutical composition of claim 19 , wherein the biodegradable liquid polyester has a weight-average molecular weight between about 5 kDa and about 40 kDa.
21. The liquid polymer pharmaceutical composition of claim 19 , wherein the composition comprises between about 20 wt % and about 40 wt % of the biodegradable liquid polyester and between about 40 wt % and about 60 wt % of the biocompatible organic solvent or combination of solvents.
22. The liquid polymer pharmaceutical composition of claim 19 , wherein a duration of release of the active pharmaceutical agent from the composition is longer than a duration of release obtained from a composition comprising a biodegradable liquid polyester without a carboxylic acid end group.